Bacterial cell division occurs in conjunction with the formation of a cytokinetic Z-ring structure comprised of FtsZ subunits. Agents that can disrupt Z-ring formation have the potential, through this unique mechanism, to be effective against several of the newly emerging multi-drug resistant strains of infectious bacteria. 1-and 12-Aryl substituted benzo[c]phenanthridines have been identified as antibacterial agents that could exert their activity by disruption of Z-ring formation. Substituted 4-and 5-amino-1-phenylnaphthalenes represent substructures within the pharmacophore of these benzo [c] phenanthridines. Several 4-and 5-substituted 1-phenylnaphthalenes were synthesized and evaluated for antibacterial activity against Staphylococcus aureus and Enterococcus faecalis. The impact of select compounds on the polymerization dynamics of S. aureus FtsZ was also assessed.
Introduction
Nosocomial infections associated with multi-drug resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) represent a major health concern. Bacterial resistance to conventional antibiotics has created a critical need for the identification of novel therapeutic antibacterial targets [1, 2] . FtsZ is an essential and highly conserved bacterial protein involved in cytokinesis [3e8] . Cell division in bacteria occurs at the site of formation of a cytokinetic Z-ring polymeric structure comprised of FtsZ subunits [3] . Several recent reviews have discussed the potential of antibacterial agents that target FtsZ, as well as recent advances in the discovery of small molecules that perturb processes in which FtsZ is involved [9e13] . FtsZ-targeting antibacterial agents can exert their disruptive effects on the Z-ring by either enhancing or inhibiting FtsZ self-polymerization [14e21] .
Sanguinarine (a) (Fig. 1 ) is a plant alkaloid that has been identified as a small molecule that alters FtsZ Z-ring formation and has modest antibacterial activity [15] . Studies in our laboratory have also shown that chelerythrine (b) has similar effects on S. aureus and Bacillus subtilis. In addition, the presence of hydrophobic functionality at either the 12-or 1-position of benzo [c] phenanthridines, as in the case of (c) and (d), significantly enhanced antibacterial activity relative to either (a) or (b) [22, 23] . These compounds (aed) have a constitutive cationic charge that can adversely affect their desired pharmacokinetic properties. 4-and 5-Substituted 1-phenylnaphthalenes represent a truncated form within the core structure of these alkaloids. Similar results were observed within a series of substituted dibenzo [a,g]quinolizinium derivatives [24] . In the present study, we examined the relative structureeactivity relationships associated with the potential antibacterial activity of several 4-and 5-substituted 1-phenylnaphthalene derivatives (Fig. 1) . Unlike sanguinarine and chelerythrine, the 4-and 5-substituted 1-phenylnaphthalene derivatives selected for synthesis and evaluation did not possess a constitutive cationic charge. Instead, they contained functionality at the site in proximity to that of the iminium cation of compounds (aed), which would to some extent be protonated at physiological pH. Using aminomethyl, alkylamidinomethyl, or alkyl guanidinomethyl derivatives, the functionality of different base strengths was assessed. Increasing the alkyl linkage to two carbons from the naphthyl-ring further increases basic properties and the degree to which these derivatives will be protonated under physiological conditions.
Chemistry
The methods used for preparation of the 4-substituted-1-phenylnaphthalenes listed in Table 1 are outlined in Scheme 1. Treatment of 4-hydroxy-1-naphthaldehyde with triflic anhydride followed by Suzuki coupling with 4-(t-butyl)phenylboronic acid provided 4-(4-(t-butyl)phenyl)-1-naphthaldehyde. This intermediate was reduced with NaBH 4 to its hydroxymethyl derivative, which was converted to its azidomethyl derivative allowing for reduction with PPh 3 to give 1. Alternatively, this benzyl alcohol intermediate was treated under Mitsunobu conditions to provide the bis-N-Boc protected guanidinomethyl intermediate, which was treated with trifluoroacetic acid to yield 3. Condensation of 4-(4-(tbutyl)phenyl)-1-naphthaldehyde with nitromethane provided the 2-nitroethylene intermediate, which was reduced with LAH to give 2. Treatment of 2 with 1,3-di-Boc-2-(trifluoromethylsulfonyl) guanidine followed by treatment with TFA provided the 2-guanidinoethyl derivative, 4.
The 5-substituted-1-phenylnaphthalenes listed in Table 1 were synthesized as outlined in Schemes 2e4. 1-Naphthaldehyde was converted to 5-bromo-1-naphthaldehyde as previously described [25] . 5-Bromo-1-naphthaldehyde was subjected to a Suzuki coupling reaction to form the appropriate 5-phenyl-1-naphthaldehyde, which was then reduced to its hydroxymethyl derivative with NaBH 4 . These 5-phenyl-1-hydroxymethylnaphthalenes were then treated under Mitsunobu conditions with 1,3-bis(t-butoxycarbonyl) guanidine followed by treatment with TFA to provide the guanidinomethyl derivatives, 8 and 14. Alternatively, 5-bromo-1-hydroxymethylnaphthalene was converted first to its bis-(N-Boc) guanidinomethyl derivative and subsequently subjected to a Suzuki coupling followed by treatment with TFA to provide the 1-guanidinomethyl-5-phenyl substituted naphthalene, 18. In the case of 5-(4-t-butylphenyl)-1-hydroxymethylnaphthalene, formation of its mesylate followed by treatment with sodium azide and reduction with triphenylphosphine provided the 1-aminomethyl derivative, 5.
The 5-[(4-trifluoromethyl)phenyl]-and 5-[(4-t-butyl
)phenyl]-1-amidinomethylnaphthalenes, 7 and 13, were synthesized from their respective bromomethylnaphthalenes, which were synthesized by treatment of their 1-hydroxymethylnaphthalene derivatives with PBr 3 .
The 1-(2-aminoethyl)-5-phenylnaphthalenes, 6 and 16, were prepared as outlined in Scheme 3. In one instance, the 1-naphthaldehyde intermediates could be condensed with nitromethane and then reduced with LAH. Alternatively, the 1-hydroxymethyl intermediates could be converted to their mesylates, reacted with NaCN and then reduced with LAH. Treatment of the requisite 2-aminoethyl derivative with 1,3-diBoc-2-(trifluoromethylsulfonyl)guanidine followed by TFA provided the 2-guanidinoethyl derivatives, 9, 15 and 19.
Preparation of 10 was accomplished by coupling 5-(4-bromophenyl)-1-naphthaldehyde with cyclopropylboronic acid, yielding an aldehyde that was reduced to its hydroxymethyl derivative, which was converted to the bis-(N-Boc)guanidinomethyl derivative and then treated with TFA. The preparation of 11 and 12 was accomplished by conversion of 5-bromo-1-naphthaldehyde to its borane ester, which was Suzuki-coupled with either 1-bromo-4-chlorobenzene or 1-bromo-4-iodobenzene. The resulting 5-(4-chlorophenyl)-1-naphthaldehyde and 5-(4-bromophenyl)-1-naphthaldehyde were reduced to their hydroxymethyl derivatives, treated under Mitsunobu conditions and subsequently treated with TFA.
Results and discussion

In vitro antibacterial activity
The antibiotic activities of several 4-and 5-substituted 1-phenylnaphthalenes are provided in Table 2 .
The data in Table 2 include the relative activities of (4-t-butyl) phenylnaphthalenes with identical substituents at either the 4-or 5-position (1e9). Among the pairs of similarly substituted derivatives are the aminomethyl derivatives, 1 and 5; 2-aminoethyl derivatives, 2 and 6; guanidinomethyl derivatives, 3 and 8 and; 2-guanidinoethyl derivatives, 4 and 9. The only notable difference in activity is that the 5-substituted guanidinoalkyl derivatives, 8 and 9, tend to be slightly more active than their comparable 4-substituted isomers, 3 and 4, in S. aureus. The data suggest that, at either the 4-or 5-position, the more basic guanidine derivatives (3, 8 and 4, 9) have a tendency to be more potent than their corresponding aminomethyl (1, 5) and 2-aminoethyl (2, 6) derivatives. While less active than the 5-guanidinomethyl derivative, 8, the 5-amidinomethyl derivative, 7, exhibited antibacterial activity comparable to 5 and 6.
Compound 8 was most active against MSSA of the 1-(4-tbutylphenyl)naphthalenes (1e9),with an MIC of 0.5 mg/mL.
Compounds 1e9 are significantly less active against MRSA, VSE and VRE. These data prompted further assessment of various 1-phenyl-5-guanidinomethylnaphthalene derivatives wherein the phenyl moiety had in place of the p-(t-butyl) substituent a cyclopropyl (10), chloro (11) , bromo (12) , or trifluoromethyl group (14e19). 5-Amidinomethyl-1-(4-trifluoromethyl)phenylnaphthalene (13) phenylnaphthalene (15) had comparable activity to 9 against MSSA, but is less active against MRSA, VSE and VRE. The addition of an o-methoxyl group to the 1-phenyl substituent did slightly improve the activity of 18 relative to 14 against Enterococcus faecalis, but slightly decreased the potency of 19 relative to 15 against S. aureus. As anticipated from the previous structureeactivity studies, the 5-(2-aminoethyl) derivatives, 16 and 17, are less active than similarly substituted 5-(guanidinoalkyl)-1-(4-trifluoromethyl)phenylnaphthalenes (15 and 19) .
All of these compounds were more active than chelerythrine against both E. faecalis strains and only in the case of the vancomycin-sensitive E. faecalis did one compound, 17, exhibit less active antibacterial activity than sanguinarine. Several of these compounds (8e10, and 15) were more active against methicillinsensitive S. aureus than either sanguinarine or chelerythrine. When evaluated for their antibacterial activity against methicillinresistant S. aureus, the more potent 1-phenylnaphthalene derivatives had comparable or slightly reduced potency relative to sanguinarine.
The various 4-and 5-susbtituted 1-phenylnaphthalenes did not exhibit pronounce cross-resistance between MSSA and MRSA, as well as between VSE and VRE, strains of bacteria. This is particularly apparent among the various 1-(t-butylphenyl)naphthalene derivatives (1e9) wherein each instance there is less than a one well difference in potency between pairs of sensitive and resistant bacterial strains. The potency of these compounds against resistant bacteria is clearly evident in a comparison of their activity to that observed with the five known antibiotics used as control agents in this study. Compounds 3, 8, and 9 had comparable MICs to vancomycin against MRSA. Compounds 1e9 all had lower MIC values (2.0e8.0 mg/mL) against VRE than the clinical antibiotics evaluated in this study.
FtsZ polymerization assays
The selection of various 4-and 5-susbtituted 1-phenylnaphthalenes evaluated in this study was based upon the reported activity of sanguinarine to alter FtsZ Z-ring formation, as well as the observation that chelerythrine has a similar effect in S. aureus and B. subtilis [15, 22] . It has been speculated that agents that alter or perturb the formation of FtsZ Z-ring could be effective against bacteria that have shown multidrug resistance, such as MRSA and VRE [6e9] . Recent studies have shown that agents that stimulate FtsZ polymerization can cause an inhibition of FtsZ Z-ring formation [14, 17, 18] . To determine whether this mechanism of antibacterial activity may be associated with the antibacterial activity observed for these 4-and 5-substituted 1-phenylnaphthalenes, we examined the effects of select compounds on the dynamics of FtsZ self-polymerization. To this end, we used a turbidity assay to monitor the self-polymerization of purified S. aureus FtsZ (SaFtsZ). In this assay, FtsZ polymerization is detected in solution by a time-dependent increase in solution turbidity, as reflected by a corresponding increase in solution absorbance at 340 nm (A 340 ).
As illustrative examples, Fig. 2 shows the time-dependent A 340 profiles of SaFtsZ in the absence and presence of 6, 8, or the nonFtsZ-targeting control antibiotic vancomycin at a concentration of 40 mg/mL. As expected, vancomycin exerts a negligible impact on SaFtsZ polymerization since its antibacterial target is the bacterial cell wall. In striking contrast to vancomycin, compounds 6 and 8 markedly increase both the kinetics and extent of SaFtsZ polymerization. Stimulation of FtsZ polymerization has been shown to be the antibacterial mechanism of action for agents such as the substituted benzamide class of compounds (e.g., PC190723) [14, 17, 18] . Our polymerization results suggest that the antibacterial activity of the phenylnaphthalenes is associated with the stimulatory impact of the compounds on the dynamics of FtsZ polymerization.
Conclusions
The antistaphylococcal activities of several 4-and 5-substituted 1-phenylnaphthalenes, as measured by their MIC values, are significant. Particularly noteworthy are the antibacterial activities observed against methicillin-resistant S. aureus, which in several instances ranged between 2.0 and 4.0 mg/mL. These values are comparable to that observed with vancomycin and are well below the MICs observed with several clinical antibiotics evaluated in this study. Similar activity against MRSA was observed for sanguinarine or chelerythrine. As these alkaloids have a constitutive cationic charge, the physico-chemical properties of several of these 1-phenylnaphthalenes, would be expected to favor their in vivo absorption and distribution. In addition, the relative MIC values for several of these 1-phenylnaphthalenes against vancomycinresistant E. faecalis (VRE) are lower than the clinical antibiotics or the two alkaloids evaluated in this study. Our studies with FtsZ polymerization suggest that the antibacterial activity of the phenylnaphthalenes is associated with the stimulatory impact of the compounds on the dynamics of FtsZ polymerization. These data suggest that compounds that interfere with FtsZ polymerization may prove to be useful in the development of antibiotics against multi-drug resistant bacteria.
Experimental
Chemistry: general methods
All reactions, unless otherwise stated, were done under nitrogen atmosphere. Reaction monitoring and follow-up were done using aluminum backed Silica G TLC plates (UV254 e Sorbent Technologies), visualizing with ultraviolet light. Flash column chromatography was done on a Combi Flash Rf Teledyne ISCO using hexane, ethyl acetate, dichloromethane, and methanol. The 1 H (400 MHz or 300 MHz) and 13 C (100 MHz) NMR spectra were done in CDCl 3 , Methanol-d 4 , and DMSO-d 6 and recorded on a Bruker Avance III (400 MHz) Multinuclear NMR Spectrometer or a Varian Unity INOVA (300 MHz) NMR Spectrometer. Data is expressed in parts per million relative to the residual nondeuterated solvent signals, spin multiplicities are given as s (singlet), d (doublet), dd (doublet of doublets), t (triplet), dt (doublet of triplets), q (quartet), m (multiplet), bs (broad singlet), and bt (broad triplet), and coupling constants (J) are reported in Hertz. Melting points were determined using Mel-temp II apparatus and are uncorrected. HRMS experiments were conducted by Washington University Resource for Biomedical and Bioorganic Mass Spectrometry Department of Chemistry. All compounds tested for biological activity were analyzed for purity using a Shimadzu LC-20AT Prominence chromatograph equipped with an SPD-20A UVeVIS detector monitoring absorbances at both 254 and 280 nm. Compounds were analyzed using a PrincetonSPHER-100 5 mM C18 reverse-phase column (150 mm Â 4.6 mm), using gradients of 0.1% TFA in water with increasing percentages of 0.1% TFA in acetonitrile. Under these solvent conditions, compounds eluted within 12 min using a flow rate of 1.0 mL/min and a gradient from 10 to 100% of acetonitrile containing 0.1% TFA.
5.2.
General procedure for the synthesis of compound (1) 5.2.1. 4-Formylnaphthalen-1-yl trifluoromethanesulfonate 4-Hydroxy-1-naphthaldehyde (250 mg, 1.45 mmol) and Et 3 N (0.4 mL, 2.9 mmol) in anhydrous DCM (20 mL) were cooled to À78 C. Tf 2 O (0.3 mL, 1.74 mmol) was slowly added to the mixture and was stirred for 30 min at À78 C. Reaction was then quickly diluted with additional DCM and washed with saturated NaHCO 3 . Organic layer was dried over sodium sulfate and concentrated. Chromatography using ISCO max gradient 30% EtOAc/hexane yielded product as a brown oil (192 mg, 44% yield); 
4-(4-(t-Butyl)phenyl)-1-naphthaldehyde
4-Formylnaphthalen-1-yl trifluoromethanesulfonate (190 mg, 0.625 mmol), 4-t-butylphenylboronic acid (134 mg, 0.75 mmol), Pd(OAc) 2 (14 mg, 0.0625 mmol), XPhos (60 mg, 0.125 mmol), and K 2 CO 3 (259 mg, 1.875 mmol) in dioxane (6 mL) and H 2 O (3 mL) were combined in a flask and degassed. Reaction was refluxed at 100 C for 1 h. Reaction was then cooled to RT, diluted with EtOAc, and washed with saturated NaHCO 3 . Organic layer was collected, dried over sodium sulfate, and concentrated. Chromatography using ISCO max gradient 30% EtOAc/hexane yielded product as a sticky golden oil (158 mg, 88% yield); 1 
(4-(4-(t-Butyl)phenyl)naphthalen-1-yl)methanol
NaBH 4 (48 mg, 1.26 mmol) was carefully added to a solution of 4-(4-(t-butyl)phenyl)-1-naphthaldehyde (120 mg, 0.42 mmol) in EtOH (5 mL). Reaction was stirred at RT for 1 h then quenched with acetone (5 drops), filtered, and concentrated. Chromatography using ISCO max gradient 40% EtOAc/hexane yielded product as a glassy white solid (95 mg, 78% yield); mp 114e115 C; 
1-(Azidomethyl)-4-(4-(t-butyl)phenyl)naphthalene
(4-(4-(t-Butyl)phenyl)naphthalen-1-yl)methanol (95 mg, 0.328 mmol) in anhydrous THF (3 mL) was cooled to 0 C. DPPA (0.14 mL, 0.656 mmol) was then added drop-wise followed by DBU (0.1 mL, 0.656 mmol). Reaction was kept stirring over ice and was warmed to RT overnight. Reaction mixture was then poured into 0.5 N HCl and extracted with EtOAc. Organic layer was collected, dried over sodium sulfate, and concentrated. Chromatography using ISCO max gradient 20% EtOAc/hexane yielded product as a white solid (78 mg, 76% yield); mp 80e81 C; 1 
5.3.
General procedure for the synthesis of compound (2) 5.
2) (168 mg, 0.583 mmol) and NH 4 OAc (52 mg, 0.67 mmol) in nitromethane (4 mL) were refluxed at 102 C for 2 h. Solvents were then evaporated. Chromatography using ISCO max gradient 10% EtOAc/hexane yielded product as a yellow solid (160 mg, 83% yield); mp 151 C; 
2-(4-(4-(t-Butyl)phenyl)naphthalen-1-yl)ethanamine (2)
To a cooled solution of 1-(4-(t-butyl)phenyl)-4-(2-nitrovinyl) naphthalene (160 mg, 0.483 mmol) in anhydrous THF (5 mL) was carefully added LAH (55 mg, 1.45 mmol) at 0 C. Reaction was then stirred at RT overnight and quenched with H 2 O over an ice bath. Reaction mixture was then diluted with EtOAc and washed with 1 N NaOH solution. Organic layer was collected, dried over sodium sulfate, and concentrated. Chromatography using ISCO max gradient 10% MeOH/DCM/0.1% NH 4 
5.4.
General procedure for the synthesis of compound (3) 5.4.
3) (40 mg, 0.14 mmol), PPh 3 (60 mg, 0.23 mmol), and 1,3-bis(t-butoxycarbonyl)guanidine (70 mg, 0.27 mmol) in anhydrous toluene (3 mL) at 0 C was added diisopropylazodicarboxylate (0.04 mL, 0.20 mmol) drop-wise over 15 min. Reaction was stirred at RT overnight then concentrated to an oil residue. Chromatography using ISCO max gradient 30% EtOAc/hexane yielded product as a white fluffy solid (70 mg, 97% yield); mp 88e90 C; 1 
2-((4-(4-(t-Butyl)phenyl)naphthalen-1-yl)methyl)guanidine (3)
To a cooled solution of 1,3-di-Boc-2-((4-(4-(t-butyl)phenyl) naphthalen-1-yl)methyl)guanidine (70 mg, 0.13 mmol) in anhydrous DCM (0.5 mL) was slowly added TFA (0.5 mL). Reaction was stirred at RT overnight then solvents were evaporated. Chromatography using ISCO max gradient 10% MeOH/DCM/0.1% NH 4 (4) 5.5.
(25 mg, 0.08 mmol), 1,3-di-Boc-2-(trifluoromethylsulfonyl)-guanidine (40 mg, 0.1 mmol), and Et 3 N (0.03 mL, 0.22 mol) in anhydrous DCM (4 mL) were stirred at RT overnight then concentrated to an oil residue. Chromatography using ISCO max gradient 10% EtOAc/ hexane yielded product as a white solid (38 mg, 84% yield); 1 
2-(2-(4-(4-(t-Butyl)phenyl)naphthalen-1-yl)ethyl)guanidine (4)
To a cooled solution of 1,3-di-Boc-2-(2-(4-(4-(t-butyl)phenyl) naphthalen-1-yl)ethyl)guanidine (36 mg, 0.07 mmol) in anhydrous DCM (0.8 mL) was slowly added TFA (0.8 mL). Reaction was stirred at RT overnight then solvents were evaporated. Chromatography using ISCO max gradient 10% MeOH/DCM/0.1% NH 4 
5.7.
General procedure for the synthesis of compound (6) 5.7.1. 2-(5-(4-(t-Butyl)phenyl)naphthalen-1-yl)acetonitrile To a solution of (5-(4-(t-butyl)phenyl)naphthalen-1-yl)methanol (5.6.2) (1.0 g, 3.4 mmol) and Et 3 N (0.8 mL, 5.8 mmol) in DCM (25 mL) at 0 C was slowly added MsCl (0.33 mL, 4.3 mmol). The reaction was stirred at 0 C for 30 min then quenched with saturated NaHCO 3 and extracted with EtOAc. Organic layer was collected, dried over magnesium sulfate, and concentrated to an oil. To this oil residue was added KCN (310 mg, 4.8 mmol) in DMSO (10 mL). The reaction was stirred at RT overnight then diluted with H 2 O and extracted with EtOAc. Extract was then washed with additional H 2 O followed by brine. Organic layer was collected, dried over magnesium sulfate, and concentrated. Chromatography using ISCO max gradient 50% EtOAc/hexane yielded product as a pale oil (6) LAH (1.0M/THF, 0.9 mL) was added drop-wise to a cooled 0 C solution of 2-(5-(4-(t-butyl)phenyl)naphthalen-1-yl)acetonitrile (85 mg, 0.28 mmol) in anhydrous THF (5 mL). The resultant mixture was then refluxed for 7 h. Reaction was cooled to 0 C and carefully treated with aqueous NaOH solution and extracted with EtOAc. Organic layer was collected, dried over magnesium sulfate, and concentrated. Chromatography using ISCO max gradient 20% 5.8. General procedure for the synthesis of compound (7) 5.8.
2) (600 mg, 2.0 mmol) in anhydrous DCM (15 mL) was cooled to 0 C and PBr 3 (0.4 mL) was added drop-wise. The reaction was stirred at 0 C for 1 h then quenched with saturated NaHCO 3 and extracted with DCM. Organic layer was collected, dried over magnesium sulfate, and concentrated to yield product as a pale oil (670 mg, 86% yield); 
2-(5-(4-(t-Butyl)phenyl)naphthalen-1-yl)acetonitrile
1-(Bromomethyl)-5-(4-(t-butyl)phenyl)naphthalene (200 mg, 0.57 mmol) and KCN (55 mg, 0.85 mmol) in DMSO (6 mL) were stirred at RT overnight. Reaction was then diluted with H 2 O and extracted with ether. Organic layer was collected, dried over magnesium sulfate, and concentrated. Chromatography using ISCO max gradient 20% EtOAc/hexane yielded product as a pale oil (120 mg, 74% yield); 1 
2-(5-(4-(t-Butyl)phenyl)naphthalen-1-yl)acetimidamide (7)
A solution of 2-(5-(4-(t-butyl)phenyl)naphthalen-1-yl)acetonitrile (120 mg, 0.4 mmol) in anhydrous Et 2 O (2 mL) was cooled to 0 C and treated with 4 N HCl/dioxane solution (2 mL). Reaction was stirred at 0 C for 4 h. The mixture was then placed in the refrigerator overnight. The precipitated solids were filtered out then treated with NH 4 OH/EtOH (6 mL) and heated to reflux for 6 h. Solvents were then evaporated. Chromatography using ISCO max gradient 20% 3% NH 4 
5.9.
General procedure for the synthesis of compound (8) 5.9.1. 1,3-Di-Boc-2-((5-(4-(t-butyl)phenyl)naphthalen-1-yl)methyl) guanidine (5-(4-(t-Butyl)phenyl)naphthalen-1-yl)methanol (5.6.2) (106 mg, 0.364 mmol), PPh 3 (100 mg, 0.38 mmol), and 1,3-bis(t-butoxycarbonyl)guanidine (132 mg, 0.52 mmol) in anhydrous toluene (3 mL) at 0 C was added diisopropylazodicarboxylate (0.1 mL, 0.52 mmol) drop-wise over 15 min. Reaction was stirred at RT overnight then 2 drops H 2 O were added, and the solution was concentrated. Chromatography using ISCO max gradient 30% EtOAc/hexane yielded product as a yellow solid (104 mg, 54% yield); 
2-((5-(4-(t-Butyl)phenyl)naphthalen-1-yl)methyl)guanidine (8)
1,3-Di-Boc-2-((5-(4-(t-butyl)phenyl)naphthalen-1-yl)methyl) guanidine (20 mg, 0.07 mmol) was stirred at RT in a mixture of anhydrous DCM (0.5 mL) and TFA (0.5 mL) overnight. Solvents were then evaporated. Chromatography using ISCO max gradient 20% 3% NH 4 
5.10.
General procedure for the synthesis of compound (9) 5.10.1. 1,3-Di-Boc-2-(2-(5-(4-(t-butyl)phenyl)naphthalen-1-yl) ethyl)guanidine 2-(5-(4-(t-Butyl)phenyl)naphthalen-1-yl)ethanamine (5.7.2) (35 mg, 0.12 mmol), 1,3-di-Boc-2-(trifluoromethylsulfonyl)-guanidine (55 mg, 0.14 mmol), and Et 3 N (0.04 mL, 0.29 mmol) in anhydrous DCM (6 mL) were stirred at RT overnight. Solvents were then evaporated. Chromatography using ISCO max gradient 20% EtOAc/ hexane yielded product as a white solid (51 mg, 81% yield); 1 
2-(2-(5-(4-(t-Butyl)phenyl)naphthalen-1-yl)ethyl) guanidine (9)
1,3-Di-Boc-2-(2-(5-(4-(t-butyl)phenyl)naphthalen-1-yl)ethyl) guanidine (40 mg, 0.09 mmol) was stirred at RT in a mixture of anhydrous DCM (0.8 mL) and TFA (0.8 mL) overnight. Solvents were then evaporated. Chromatography using ISCO max gradient 15% 3% NH 4 
(5-(4-Cyclopropylphenyl)naphthalen-1-yl)methanol
(5-(4-Bromophenyl)naphthalen-1-yl)methanol (130 mg, 0.415 mmol), cyclopropylboronic acid (71 mg, 0.83 mmol), Pd(OAc) 2 (5 mg, 0.021 mmol), tricyclohexylphosphine (12 mg, 0.0415 mmol), and K 3 PO 4 (308 mg, 1.45 mmol) were combined in a flask with toluene (3 mL) and H 2 O (1 mL) and degassed. Reaction mixture was then refluxed at 100 C for 3 h. Solution was cooled to RT then diluted with EtOAc and washed with saturated NaHCO 3 . Organic layer was dried over sodium sulfate and concentrated. Chromatography using ISCO max gradient 35% EtOAc/hexane yielded product as a brown oil (86 mg, 75% yield); 1 
2-((5-(4-Cyclopropylphenyl)naphthalen-1-yl)methyl) guanidine (10)
To a solution of (5-(4-cyclopropylphenyl)naphthalen-1-yl) methanol (80 mg, 0.292 mmol), PPh 3 (115 mg, 0.584 mmol), and 1,3-bis(t-butoxycarbonyl)guanidine (151 mg, 0.438 mmol) in anhydrous toluene (3 mL) at 0 C was added diisopropylazodicarboxylate (0.09 mL, 0.438 mmol) drop-wise over 15 min. Reaction was stirred for 3 h at RT then 2 drops H 2 O were added, and the solution was concentrated. Solid was then dissolved in DCM and passed through silica column and resulting crude product was then re-dissolved in anhydrous DCM (1.5 mL) and cooled to 0 C. TFA (1.5 mL) was then added. Reaction was taken off ice bath and stirred at RT for 2 h then solvents were evaporated. Solid was then taken back up in DCM and precipitate was filtered off yielded product as a gummy tan solid (18 
5.12.
General procedure for the synthesis of compound (11) 5.12. 
(5-(4-Chlorophenyl)naphthalen-1-yl)methanol
5-(4-Chlorophenyl)-1-naphthaldehyde (160 mg, 0.6 mmol) and NaBH 4 (16 mg, 0.42 mmol) in 95% EtOH/MeOH (10 mL) were stirred at RT for 1 h. Reaction mixture was then filtered and filtrate concentrated. Residue was then taken back up in DCM and washed with saturated NaHCO 3 solution followed by brine. Organic layer was collected, dried over magnesium sulfate, and concentrated. Chromatography using ISCO max gradient 30% EtOAc/hexane yielded product as a clear oil (160 mg, quantitative); 1 
1,3-Di-Boc-2-((5-(4-chlorophenyl)naphthalen-1-yl)methyl) guanidine
To a solution of (5-(4-chlorophenyl)naphthalen-1-yl)methanol (50 mg, 0.186 mmol), PPh 3 (73 mg, 0.278 mmol), and 1,3-bis(tbutoxycarbonyl)guanidine (96 mg, 0.37 mmol) in anhydrous toluene (3 mL) at 0 C was added diisopropylazodicarboxylate (0.06 mL, 0.31 mmol) drop-wise over 15 min. Reaction was stirred at RT overnight, and the solution was then concentrated to an oil residue. Chromatography using ISCO max gradient 30% EtOAc/hexane yielded product as a pale solid (46 mg, 48% yield); (11) 1,3-Di-Boc-2-((5-(4-chlorophenyl)naphthalen-1-yl)methyl) guanidine (46 mg, 0.09 mmol) in a mixture of anhydrous DCM (0.8 mL) and TFA (0.8 mL) was stirred at RT overnight. Solvents were then evaporated. Chromatography using ISCO max gradient 20% 3% NH 4 (12) 5.13.1. 1,3-Di-Boc-2-((5-(4-bromophenyl)naphthalen-1-yl)methyl) guanidine To a solution of (5-(4-bromophenyl)naphthalen-1-yl)methanol (5.11.3) (40 mg, 0.128 mmol), PPh 3 (60 mg, 0.23 mmol), and 1,3-bis(t-butoxycarbonyl)guanidine (66 mg, 0.26 mmol) in anhydrous toluene (3 mL) at 0 C was added diisopropylazodicarboxylate (0.04 mL, 0.20 mmol) drop-wise over 15 min. Reaction was stirred at RT overnight, and the solution was then concentrated to an oil residue. Chromatography using ISCO max gradient 30% EtOAc/ hexane yielded product as a pale solid (46 mg, 47% yield); 1 
2-((5-(4-Chlorophenyl)naphthalen-1-yl)methyl)guanidine
2-((5-(4-Bromophenyl)naphthalen-1-yl)methyl)guanidine (12)
1,3-Di-Boc-2-((5-(4-bromophenyl)naphthalen-1-yl)methyl) guanidine (34 mg, 0.06 mmol) in a mixture of anhydrous DCM (0.8 mL) and TFA (0.8 mL) was stirred at RT overnight. Solvents were then evaporated. Chromatography using ISCO max gradient 20% 3% NH 4 5.14. General procedure for the synthesis of compound (13) 5.14.1. 5-(4-(Trifluoromethyl)phenyl)-1-naphthaldehyde 5-Bromo-1-naphthaldehyde (500 mg, 2.1 mmol), 4-trifluoromethylphenylboronic acid (620 mg, 3.2 mmol), and K 2 CO 3 (880 mg, 6.4 mmol) in dioxane (15 mL) and H 2 O (3 mL) were degassed and Pd(PPh 3 ) 4 (73 mg, 0.06 mmol) was quickly added. Reaction was then refluxed at 100 C for 5 h then cooled to RT. Solution was dried over magnesium sulfate, filtered, and concentrated. Chromatography using ISCO max gradient 30% EtOAc/ hexane yielded product as a pale solid (560 mg, 88% yield); mp 78e 80 C; 
(5-(4-(Trifluoromethyl)phenyl)naphthalen-1-yl)methanol
A mixture of 5-(4-(trifluoromethyl)phenyl)-1-naphthaldehyde (350 mg, 1.16 mmol) and NaBH 4 (31 mg, 0.82 mmol) in 95% EtOH/MeOH (15 mL) was stirred at RT for 1 h. Reaction was then filtered and filtrate was concentrated. Residue was taken back up in EtOAc and washed with saturated NaHCO 3 solution followed by brine. Organic layer was collected, dried over magnesium sulfate, and concentrated. Chromatography using ISCO max gradient 30% EtOAc/hexane yielded product as a white solid (350 mg, quantitative); mp 98 C; 
2-(5-(4-(Trifluoromethyl)phenyl)naphthalen-1-yl) acetonitrile
(5-(4-(Trifluoromethyl)naphthalen-1-yl)methanol (300 mg, 0.99 mmol) in anhydrous DCM (10 mL) was cooled to 0 C and PBr 3 (0.14 mL) was added drop-wise. The reaction was stirred at 0 C for 1 h then quenched with saturated NaHCO 3 and extracted with DCM. Organic layer was collected, dried over magnesium sulfate, and concentrated to yield crude product as a pale gum which was taken forward without further purification. This crude 1-(bromomethyl)-5-(4-(trifluoromethyl)phenyl)naphthalene (300 mg, 0.82 mmol) and KCN (100 mg, 1.5 mmol) in DMSO were stirred at RT overnight. Reaction was then diluted with H 2 O and extracted with ether. Organic layer was collected, dried over magnesium sulfate, and concentrated. Chromatography using ISCO max gradient 20% EtOAc/ hexane yielded product as a white solid (260 mg, 85% yield over two steps); mp 44e45 C; 
2-(5-(4-(Trifluoromethyl)phenyl)naphthalen-1-yl) acetimidamide (13)
A solution of 2-(5-(4-(trifluoromethyl)phenyl)naphthalen-1-yl)acetonitrile (100 mg, 0.32 mmol) in anhydrous Et 2 O (2 mL) was cooled to 0 C and treated with 4 N HCl/dioxane solution (2 mL). Reaction was stirred at 0 C for 4 h. The mixture was then placed in the refrigerator overnight. The precipitated solids were filtered out then treated with NH 4 OH/EtOH (5 mL) and heated to reflux for 6 h. Solvents were then evaporated. Chromatography using ISCO max gradient 20% 3% NH 4 (14) 5.15.
To a solution of (5-(4-(trifluoromethyl)phenyl)naphthalen-1-yl)methanol (5.14.2) (40 mg, 0.13 mmol), PPh 3 (55 mg, 0.21 mmol), and 1,3-bis(t-butoxycarbonyl)guanidine (70 mg, 0.27 mmol) in anhydrous toluene (3 mL) at 0 C was added diisopropylazodicarboxylate (0.04 mL, 0.20 mmol) drop-wise over 15 min. Reaction was stirred at RT overnight, and the solution was then concentrated to an oil residue. Chromatography using ISCO max gradient 30% EtOAc/hexane yielded product as a white glassy residue (56 mg, 80% yield); 1 (15) 1,3-Di-Boc-2-(2-(5-(4-(trifluoromethyl)phenyl)naphthalen-1-yl) ethyl)guanidine (20 mg, 0.036 mmol) was stirred at RT in a mixture of anhydrous DCM (0.5 mL) and TFA (0.5 mL) overnight. Solvents were then evaporated. Chromatography using ISCO max gradient 20% 3% NH 4 
2-(5-(2-Methoxy-4-(trifluoromethyl)phenyl)naphthalen-1-yl)acetonitrile
To a solution of (5-(2-methoxy-4-(trifluoromethyl)phenyl) naphthalen-1-yl)methanol (180 mg, 0.54 mmol) and Et 3 N (0.15 mL, 1.08 mmol) in DCM (5 mL) was added MsCl (0.06 mL, 0.81 mmol), and the reaction mixture was stirred at RT overnight. Reaction was then diluted with DCM and washed with saturated NaHCO 3 . Organic layer was dried over sodium sulfate and concentrated without further purification. This crude (5-(2-methoxy-4-(trifluoromethyl)phenyl)naphthalen-1-yl)methyl methanesulfonate (150 mg, 0.37 mmol) was combined with KCN (48 mg, 0.73 mmol) in anhydrous DMF (3 mL) and stirred at RT overnight. Reaction mixture was then diluted with EtOAc and washed with 10% LiCl solution. Organic layer was dried over sodium sulfate and concentrated. Chromatography using ISCO max gradient 30% EtOAc/hexane yielded product as clear oil (125 mg, 68% yield over two steps); 3.77 (s, 3H); 13 
General procedure for the synthesis of 2-(5-(2-aminoethyl) naphthalen-1-yl)-5-(trifluoromethyl)phenol (17)
To a cooled solution of 2-(5-(2-methoxy-4-(trifluoromethyl) phenyl)naphthalen-1-yl)ethanamine (28 mg, 0.081 mmol) in anhydrous DCM (4 mL) was added BBr 3 (1.0 M in DCM, 0.41 mL) drop-wise. The solution was then stirred at RT for 3 h and reaction was placed back over ice. H 2 O was slowly dripped into the flask to quench the remaining BBr 3 and mixture was then diluted with additional DCM and washed with NaHCO 3 . Organic layer was dried over sodium sulfate and concentrated. Chromatography using ISCO max gradient 10% MeOH/DCM to yield product as a clear oil (13 To a cooled solution of 1,3-di-Boc-2-(2-(5-(2-methoxy-4-(trifluoromethyl)phenyl)naphthalen-1-yl)ethyl)guanidine (35 mg, 0.06 mmol) in anhydrous DCM (1 mL) was added TFA (1 mL). Reaction was taken off ice bath and stirred at RT for 2 h then solvents were evaporated. Chromatography using ISCO max gradient 10% MeOH/DCM yielded product as a clear oil (19 mg 
Minimum inhibitory concentration (MIC) assays
MIC assays were conducted in accordance with Clinical Laboratory Standards Institute (CLSI) guidelines for broth microdilution [26] . The following bacterial strains were included in these assays: S. aureus 8325-4 (MSSA); S. aureus ATCC 33591 (MRSA); E. faecalis ATCC 19433 (VSE) and; E. faecalis ATCC 51575 (VRE). Log-phase bacteria were added to 96-well microtiter plates (at 10 5 CFU/mL) containing 2-fold serial dilutions of compound or comparator drug (at concentrations ranging from 64 to 0.031 mg/mL) in cation-adjusted Mueller-Hinton (CAMH) broth (for the S. aureus assays) or brain-heart infusion (BHI) broth (for the E. faecalis assays). In the MRSA assays, the CAMH broth was supplemented with 2% NaCl. The final volume in each well was 0.1 mL and the microtiter plates were incubated aerobically for 24 h at 37 C. Bacterial growth was then monitored by measuring OD 600 using a VersaMax Ò plate reader (Molecular Devices, Inc.), with the MIC being defined as the lowest compound concentration at which growth was !90% inhibited.
Expression and purification of S. aureus FtsZ (SaFtsZ)
The FtsZ gene from S. aureus was amplified by polymerase chain reaction (PCR) from the S. aureus genome obtained from ATCC (ATCC 33591-D). The amplified gene product was then ligated into the pET-22b(þ) cloning vector (Novagen-EMD Chemicals, Inc.), with the sequence of the final recombinant plasmid (pETSAFtsZ) being verified by sequence analysis and used to transform E. coli BL21 (DE3) cells.
A single colony of pETSAFtsZ-transformed E. coli cells was used to inoculate Luria Bertani media containing 100 mg/mL of ampicillin (LB-amp) and grown overnight at 37 C. 20 mL of the culture was diluted into 4 L of LB-amp and grown until an optical density at 600 nm (OD 600 ) of 0.4, at which point FtsZ production was induced by addition of isopropyl b-D-1-thiogalactopyranoside (IPTG) to a final concentration of 1 mM. Following addition of IPTG, the cultures were incubated for an additional 3 h at 37 C. Cells were then harvested by centrifugation at 4 C and 4000Âg in a swinging bucket Sorvall RC-3BPþ centrifuge with rotor H-6000 for 20 min. The bacterial cell pellet was washed with ice cold 50 mM Tris$HCl (pH 8.0), 0.5 M NaCl and re-pelleted by centrifugation as described above. The washed bacterial pellet was stored at À20 C. The dialyzed material was loaded onto a MonoQ 10/100 anion exchange column at 1 mL/min and washed with 5 column volumes of TKEGE buffer at 1 mL/min. The column was eluted at 4 C with a 0e60% (v/v) linear gradient (120 mL total volume) of the following two buffers: (i) TKEGE (containing 50 mM KCl) and (ii) TKEGE containing 1 M KCl instead of 50 mM KCl. The rate of elution was maintained at 1 mL/min. Fractions were assayed for FtsZ by SDS-PAGE analysis on a 10e15% Tris$HCl polyacrylamide gel. FtsZ elutes at 250e350 mM KCl. The FtsZ containing fractions were pooled and dialyzed against 2 L of TKEGE buffer. The dialyzed fractions were concentrated, if necessary, to 5 mL and loaded onto a Superdex-200 size exclusion column, with TKEGE buffer as the running buffer at 0.25 mL/min. SaFtsZ-containing fractions were detected by SDS-PAGE as above. Peak fractions containing the pure SaFtsZ were pooled and concentrated using Amicon Ò Ultra centrifugal filters (Millipore Corp.). Quantitation was performed spectrophotometrically at 595 nm using a colorimetric protein assay kit (Bio-Rad) and bovine serum albumin as the standard. The final FtsZ concentration was w8 mg/mL and the protein was w90% pure as determined by SDS-PAGE analysis.
FtsZ polymerization assays
Polymerization of SaFtsZ was monitored using a microtiter plate-based turbidity assay. Experiments were conducted at 25 C in solution containing 50 mM Tris$HCl (pH 7.4), 50 mM KCl, 2 mM magnesium acetate and 1 mM GTP. GTP was combined with vehicle, compound, or control drug and the reactions were initiated by addition of the protein at a final concentration of 10 mM. The reactions (100 mL total volume) were assembled in half-volume, flat-bottom 96-well microtiter plates and their absorbances at 340 nm were continuously monitored using a VersaMax Ò plate reader over a time period of 300 min.
